Concord Biotech Limited vs Mankind Pharma Limited
Last updated: 24 October 2026
Concord Biotech vs. Mankind Pharma: A MoneyDock Comparison
In the dynamic landscape of the Indian pharmaceutical sector, Concord Biotech Limited and Mankind Pharma Limited stand out as significant players, each carving its niche. Concord Biotech, known for its expertise in fermentation-based biopharmaceutical products, particularly immunosuppressants and oncology drugs, operates largely in the niche of biopharmaceuticals. Mankind Pharma, on the other hand, has established a formidable presence in the domestic market with a wide range of pharmaceutical formulations, over-the-counter (OTC) products, and veterinary medicines. Both companies represent different facets of the healthcare industry, making a comparison of their financial metrics insightful for investors looking to diversify or focus their portfolios within the pharma space.
Key Financial Metrics Comparison
| Metric | Concord Biotech (CONCORDBIO.NS) | Mankind Pharma (MANKIND.NS) |
|---|---|---|
| Current Price | ₹1229.30 | ₹2212.60 |
| 52-Week High | ₹1579.40 | ₹2617.90 |
| 52-Week Low | ₹1014.80 | ₹1927.40 |
| 1-Year Return | -7.65% | 4.80% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Who Wins on Key Metrics?
Valuation: Unfortunately, with the Trailing P/E and Market Cap listed as 'N/A' for both companies, a direct comparison on traditional valuation metrics is not possible based on the provided data. However, looking at the current price, Mankind Pharma trades at a significantly higher price point (₹2212.60) compared to Concord Biotech (₹1229.30). Without P/E ratios or market caps, it's impossible to determine which stock is 'cheaper' relative to its earnings or size.
Returns: On the front of 1-Year Returns, Mankind Pharma clearly outperforms Concord Biotech. Mankind Pharma has delivered a positive return of 4.80%, indicating growth over the past year. In stark contrast, Concord Biotech has posted a negative return of -7.65% over the same period. This suggests that Mankind Pharma has been a more rewarding investment in the short to medium term based on this metric, while Concord Biotech has seen a decline in its stock value.
Stability: To assess stability, we can look at the proximity of the current price to the 52-week high and low. Concord Biotech's current price of ₹1229.30 is closer to its 52-week low (₹1014.80) than its high (₹1579.40), suggesting it has been under some selling pressure or has not recovered significantly from its lows. Its price is approximately 21.91% off its 52-week high. Mankind Pharma, at ₹2212.60, is also closer to its 52-week low (₹1927.40) than its high (₹2617.90), being approximately 15.48% off its 52-week high. While both are off their highs, Mankind Pharma appears to have experienced less volatility or has maintained its value better relative to its peak compared to Concord Biotech within the last year, suggesting slightly better stability in performance. However, without more long-term data, a definitive statement on long-term stability is difficult.
MoneyDock Verdict
For Aggressive Investors: Given Mankind Pharma's positive 1-year return and its relatively strong position in the market compared to Concord Biotech's negative return, it might appeal more to aggressive investors looking for current momentum. However, without valuation metrics, the risk profile is incomplete.
For Conservative Investors: Neither stock presents a clear conservative choice without P/E ratios and market caps to understand underlying value and risk. Concord Biotech's negative return might deter conservative investors seeking capital preservation. Mankind Pharma, while showing positive returns, still requires a deeper dive into its fundamentals beyond price action for a conservative approach.
For Long-Term SIP Investors: For long-term SIP investors, Mankind Pharma appears to be the more favorable choice based on its positive 1-year return, indicating a growing trend that could benefit from rupee-cost averaging. Concord Biotech, with its negative return, would require investors to believe in a strong turnaround story and be comfortable averaging down during a period of decline. Both would benefit from a more comprehensive fundamental analysis, but based purely on the given price and return data, Mankind Pharma shows more short-term promise.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.